Effectiveness of Nefopam for Thermoregulation During Surgery
Primary Purpose
Hypothermia
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Nefopam Low dose
Nefopam High dose
Sponsored by
About this trial
This is an interventional treatment trial for Hypothermia focused on measuring Nefopam, Pharmacokinetics, Shivering,, Thermoregulation, Anesthesia
Eligibility Criteria
Inclusion Criteria:
- Normal healthy volunteers ages 18-40
Exclusion Criteria:
- history of alcohol or drug abuse
Sites / Locations
- Department of Anesthesiology, University of Bern
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Nefopam low dose
Nefopam high dose
Arm Description
Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
Outcomes
Primary Outcome Measures
V1
Volume of distribution 1
V2
Volume of distribution2
CLel
Clearance
CLdist
Clearance distribution
Secondary Outcome Measures
Full Information
NCT ID
NCT03122665
First Posted
October 26, 2016
Last Updated
June 16, 2020
Sponsor
The Cleveland Clinic
Collaborators
Laboratoires Biocodex (Montrouge, France)
1. Study Identification
Unique Protocol Identification Number
NCT03122665
Brief Title
Effectiveness of Nefopam for Thermoregulation During Surgery
Official Title
Effectiveness of Nefopam for Thermoregulation During Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
August 2004 (undefined)
Primary Completion Date
January 2006 (Actual)
Study Completion Date
January 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Cleveland Clinic
Collaborators
Laboratoires Biocodex (Montrouge, France)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Nefopam may help blunt thermoregulatory defenses, thus facilitating induction of therapeutic hypothermia
Detailed Description
Hypothermia, whether therapeutically induced or unintentional, triggers thermoregulatory defenses including vasoconstriction and shivering. Nefopam, a non-opioid, nonsteroidal centrally acting analgesic, has an opioid-sparing effect and anti-shivering potency without sedation, making it an ideal candidate to counteract thermoregulatory shivering.
Since complete compartmental pharmacokinetics (PK) are lacking this prospective, randomized, double-blind study in 8 volunteers was set to investigate the PK of arterial nefopam samples with non-linear mixed effect modelling. A two compartment mammillary model independent of covariates was found to describe the data best and could be implemented to drive automated pumps, achieving and maintaining a desired plasma concentration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypothermia
Keywords
Nefopam, Pharmacokinetics, Shivering,, Thermoregulation, Anesthesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Volunteers given two doses of nefopam in a crossover protocol.
Masking
ParticipantInvestigator
Masking Description
Blinded drug containers.
Allocation
Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nefopam low dose
Arm Type
Active Comparator
Arm Description
Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
Arm Title
Nefopam high dose
Arm Type
Active Comparator
Arm Description
Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
Intervention Type
Drug
Intervention Name(s)
Nefopam Low dose
Other Intervention Name(s)
Low
Intervention Description
Continuous intravenous infusion at 0.5 mg/ml for three hours.
Intervention Type
Drug
Intervention Name(s)
Nefopam High dose
Other Intervention Name(s)
High
Intervention Description
Continuous intravenous infusion at 1.0 mg/ml for three hours.
Primary Outcome Measure Information:
Title
V1
Description
Volume of distribution 1
Time Frame
three hours of infusion
Title
V2
Description
Volume of distribution2
Time Frame
three hours of infusion
Title
CLel
Description
Clearance
Time Frame
three hours of infusion
Title
CLdist
Description
Clearance distribution
Time Frame
three hours of infusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Normal healthy volunteers ages 18-40
Exclusion Criteria:
history of alcohol or drug abuse
Facility Information:
Facility Name
Department of Anesthesiology, University of Bern
City
Bern
State/Province
Freiburgstrasses
ZIP/Postal Code
3010
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effectiveness of Nefopam for Thermoregulation During Surgery
We'll reach out to this number within 24 hrs